v3.26.3
Insider Trading Arrangements
3 Months Ended
Sep. 30, 2026
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

Rule 10b5-1 Trading Arrangements. During the three months ended September 30, 2026, our officers (as defined in Rule 16a-1(f) under the Exchange Act) set forth below adopted or terminated a “Rule 10b5-1 trading arrangement” as that term is defined in Item 408(a) of Regulation S-K, all of which were entered into during an open trading window in accordance with our Securities Trading Policy and all of which were intended to satisfy Rule 10b5-1(c).

•
On August 12, 2026, Jay R. Luly, Ph.D., our President, Chief Executive Officer and Director, adopted a Rule 10b5-1 trading plan providing for the sale of up to 96,005 shares of our common stock, including shares vested under performance stock units and restricted stock units, as well as shares vesting under outstanding stock options which expire in November 2027, so long as the market price of our common stock is higher than certain minimum threshold prices specified in the plan in various periods between November 19, 2026 (subject to the applicable cooling-off period) and April 30, 2027, or such earlier date as all authorized sales under the plan are completed.
•
On August 13, 2026, Tara L. Kieffer, Ph.D., our Chief Operating Officer, adopted a Rule 10b5-1 trading plan providing for the sale of up to 83,419 shares of our common stock, including shares vested under performance stock units and restricted stock units, as well as shares vesting under outstanding stock options, so long as the market price of our common stock is higher than certain minimum threshold prices specified in the plan in various periods between November 19, 2026 (subject to the applicable cooling-off period) and November 24, 2027, or such earlier date as all authorized sales under the plan are completed.
•
On September 9, 2026, Scott Rottinghaus, M.D., our Chief Medical Officer, adopted a Rule 10b5-1 trading plan providing for the sale of up to 22,037 shares of our common stock, including shares vested under performance stock units and restricted stock units, so long as the market price of our common stock is higher than certain minimum threshold prices specified in the plan in various periods between April 1, 2027 and August 2, 2027, or such earlier date as all authorized sales under the plan are completed.

 

Except as set forth above, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-rule 10b5-1 trading arrangement,” as each term is defined in item 408(a) of Regulation S-K.
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Jay R. Luly  
Trading Arrangements, by Individual  
Name Jay R. Luly
Title President, Chief Executive Officer and Director
Rule 10b5-1 Arrangement Adopted true
Adoption Date August 12, 2026
Arrangement Duration 162 days
Aggregate Available 96,005
Tara L. Kieffer  
Trading Arrangements, by Individual  
Name Tara L. Kieffer
Title Chief Operating Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date August 13, 2026
Arrangement Duration 370 days
Aggregate Available 83,419
Scott Rottinghaus  
Trading Arrangements, by Individual  
Name Scott Rottinghaus
Title Chief Medical Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date September 9, 2026
Arrangement Duration 123 days
Aggregate Available 22,037